LAPTM4B and esophageal cancer: LAPTM4B could be a diagnostic, prognostic or therapeutic factor in hepatocellular carcinoma, breast cancer, bladder cancer, renal clear cell carcinoma, nasopharyngeal cancer, lung cancer, osteosarcoma, glioblastoma, gastric cancer, pancreatic ductal adenocarcinoma, ovarian cancer, neck squamous cell carcinomas, prostate cancer, endometrial cancer, colorectal cancer, gallbladder carcinoma, esophageal cancers, cervical carcinoma, melanoma, pancreatic carcinoma and AML and so on (17, 18, 20, 30–51).